title: Safety and tolerability of apomorphine SL (Uprima).
abstract: The side effect profile of apomorphine SL (2-6 mg) has been determined in clinical studies of over 5000 patients using over 120 000 doses. Apomorphine, 2 and 3 mg, has been shown to have an excellent safety profile. The most commonly occurring side effects (<7%), nausea, headache and dizziness, tend to be mild and not compliance limiting. Neither the incidence nor the nature of the side effects is significantly affected by common co-morbidites or by the use of many concurrent medications. Over this dose range there is little evidence of vasoactivity; there is little change in haemodynamic baseline and there is no synergistic effect with nitrates. Although syncope can occur at higher doses, it is rarely observed at approved doses (<0.2%).
authors.affiliation: Abbott International, Abbott Laboratories, Abbott Park, IL 60064-3537, USA. Stan.bukofzer@ln.ssw.abbott.com
authors.forename: S
authors.initials: S
authors.lastname: Bukofzer
authors.forename: N
authors.initials: N
authors.lastname: Livesey
mesh_terms: D000286:Administration, Sublingual; D001058:Apomorphine / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000008:administration & dosage* / Q000009:adverse effects* / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012449:Safety
chemical_list: D018491:Dopamine Agonists; D001058:Apomorphine